MONOTHERAPY WITH PIPERACILLIN/TAZOBACTAM VERSUS CEFEPIME AS EMPIRICAL THERAPY FOR FEBRILE NEUTROPENIA IN PEDIATRIC CANCER PATIENTS: A Randomized Comparison

REFERENCES

• Hughes W T, Armstrong D, Bodey G P, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–751, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Viscoli C, Castagnola E, Caniggia M, et al. Italian guidelines for the management of infectious complications in pediatric oncology: empirical antimicrobial therapy of febrile neutropenia. Oncology 1998; 55: 489–500, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Gaya H. Empirical therapy of infections in neutropenic patients. Br J Hematol. 1998; 101: 5–9, [CSA]
   PubMed Web of Science ®Google Scholar
• Klastersky J. Empirical antibiotic therapy in neutropenic cancer patients. Eur J Cancer 1993; 29: 6–10, [CSA]
   Web of Science ®Google Scholar
• Kebudi R, Gorgün O, Ayan I, Gurler N, Akici F, Toreci K. Randomized comparison of cefepime versus ceftazidime monotherapy for fever and neutropenia in children with solid tumors. Med Pedaitr Oncol. 2001; 36: 434–441, [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Hung K C, Chiu H H, Tseng Y C, et al. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy. J Microbiol Immunol Infect 2003; 36: 254–259, [PUBMED], [CSA]
   PubMedGoogle Scholar
• Düzova A, Kutluk T, Kanra G, et al. Monotherapy with meropenem versus combination therapy with piperacillin plus amikacin as empiric therapy for neutropenic fever in children with lymphoma and solid tumors. Turk J Pediatr 2001; 43: 105–109, [CSA]
   PubMed Web of Science ®Google Scholar
• Biron P, Fuhrmann C, Cure H, et al. Cefepime versus imipenem-cilastatin as emprical monotherapy in 400 febrile patients with short duration neutropenia. J Antimicrob Chemother 1998; 42: 511–518, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ramphal R. Is monotherapy for febrile neutropenia still a viable alternative?. Clin Infect Dis. 1999; 29: 508–514, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Ramphal R, Gucalp R, Rotstein C, Cimino M, Oblon D. Clinical experince with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am J Med 1996; 100: 83S–89S, [PUBMED], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Çorapçioglu F, Sarper N. Cefepime versus ceftazidime+amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost. Pediatr Hematol Oncol. 2005; 22: 59–70, [CSA]
   PubMed Web of Science ®Google Scholar
• Gorschlüter M, Hahn C, Fixson A, et al. Piperacillin–tazobactam is more effective than ceftriaxone plus gentamicin in febrile neutropenic patient with hematological malignancies: a randomized comparison. Support Care Cancer 2003; 11: 362–370, [CSA]
   PubMed Web of Science ®Google Scholar
• Yamamura D, Gucalp R, Carlisle P, Cimino M, Roberts J, Rotstein C. Open randomized study of cefepime versus piperacillin-gentamicin for treatment of febrile neutropenic cancer patients. Antimicrob Agents Chemother. 1997; 41: 1704–1708, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Fleischhack G, Schmidt-Niemann M, Wulff B, et al. Piperacillin, beta-lactam inhibitor plus gentamicin as empirical therapy of a sequential regimen in febrile neutropenia of pediatric cancer patients. Support Care Cancer 2001; 9: 372–379, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Cometta A, Zinner S, De Bock R, et al. Piperacillin–tazobactam plus amikacin versus ceftazidime plus amikacin as empiric therapy for fever in granulucytopenic patients with cancer. Antimicrob Agents Chemoter 1995; 39: 445–452, [CSA]
   PubMed Web of Science ®Google Scholar
• Hess U, Böhme C, Rey K, Senn H J. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients. Support Care Cancer. 1998; 6: 402–409, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Del Favero A, Menichetti F, Martino P, et al. A multicenter, double-blind, placebo-controlled trial comparing piperacillin-tazobactam with and without amikacin as empiric therapy for febrile neutropenia. Clin Infect Dis 2001; 33: 1295–1301, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Le Guyader N, Auvrignon A, Vu-Thien H, Portier E, Tabone M D, Leverger G. Piperacillin–tazobactam and netilmicin as a safe and efficacious empirical treatment of febrile neutropenic children. Support Care Cancer. 2004; 12: 720–724, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Aksoylar S, Çetingül N, Kantar M, Karapinar D, Kavakli K, Kansoy S. Meropenem plus amikacin versus piperacillin–tazobactam plus netilmicin as empiric therapy for high-risk febrile neutropenia in children. Pediatr Hematol Oncol. 2004; 21: 115–123, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kutluk T, Kurne O, Akyüz C, et al. Cefepime vs. meropenem as empirical therapy for neutropenic fever in children with lymphoma and solid tumors. Pediatr Blood Cancer 2004; 42: 284–286, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Mustafa M M, Carlson L, Tkaczewski I, McCracken G H, Jr, Buchanan G R. Comparative study of cefepime versus ceftazidime in the empiric treatment of pediatric cancer patients with fever and neutropenia. Pediatr Infect Dis J. 2001; 20: 362–369, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Dues J M, Siebor E, Pechinot A, Cordin X, Chamard-Neuwirth C, Kazmierczak A. In vitro antibacterial activity of piperacillin-tazobactam in combination with netilmicin or amikacin against Enterobacteriaceae resistant to amoxicillin. Pathol Biol. 1995; 43: 208–214, [CSA]
   PubMedGoogle Scholar
• Thabaut A, Meyran M. In vitro activity of piperacillin-tazobactam on 224 isolats of P. aeruginosa according to beta-lactamase production. Pathol Biol 1991; 39: 361–366, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Arguedas A, Sifuentes-Osornio J, Loaiza C, Herrera M, Corrales J C, Mohs E. An open, multicenter clinical trial of piperacillin/tazobactam in the treatment of pediatric patients with intra-abdominal infections. J Chemother. 1996; 8: 130–136, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Cometta A, Kern W V, De Bock R, et al. Vancomycin versus placebo for treating persistent fever in patients with neutropenic cancer receiving piperacillin–tazobactam monotherapy. Clin Infect Dis 2003; 37: 382–389, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Kelsey S M, Weinhardt B, Pocock C E, Shaw E, Newland A C. Piperacillin/tazobactam plus gentamicin as empirical therapy for febrile neutropenic patients with hematological malignancy. J Chemother. 1992; 4: 281–285, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Bohme A, Shah P M, Stille W, Hoelzer D. Piperacillin/tazobactam versus cefepime as initial empirical antimicrobial therapy in febrile neutropenia patients: a prospective randomized pilot study. Eur J Met Res. 1998; 3: 324–330, [CSA]
   Google Scholar
• Reed M D, Goldfarb C, Yamashita T S, Lemon E, Blumer J. Single-dose pharmacokinetics of piperacillin and tazobactam in infants and children. Antimicrob Agents Chemother. 1994; 38: 2817–2826, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar
• Nürnberger W, Bönig H, Burdach S, Göbel U. Tolerability of piperacillin/tazobactam in children and adolescence after high dose radio/chemotherapy and autologous stem cell transplantation. Infection. 1998; 26: 65–67, [CSA]
   PubMed Web of Science ®Google Scholar
• Castagnola E, Paula D, Giacchino R, Rossi R, Viscoli C. Economic aspects of empiric antibiotic therapy for febrile neutropenia in children with cancer. Support Care Cancer. 1998; 6: 524–528, [PUBMED], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Agaoglu L, Devecioglu O, Anak S, et al. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey. J Chemother 2001; 13: 281–287, [PUBMED], [CSA]
   PubMed Web of Science ®Google Scholar